Cochrane · systematic review · CD012433
Oxcarbazepine add‐on for drug‐resistant focal epilepsy
Bresnahan, R, Atim‐Oluk, M, Marson, AG · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 4 · 57.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oxcarbazepine compared to control for drug‐resistant focal epilepsy
Population: drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Median percentage seizure reduction per 28 days Oxcarbazepine vs control | no estimate extracted | 5 studies · 1494 participants | Moderate Downgraded: risk of bias |
50% or greater reduction in seizure frequency Oxcarbazepine vs control | RR 1.8 [1.27, 2.56] | 6 studies · 1593 participants | Low Downgraded: risk of bias |
Ataxia Oxcarbazepine vs control | RR 2.54 [0.86, 7.54] | 5 studies · 1227 participants | Moderate Downgraded: risk of bias |
Hyponatraemia Oxcarbazepine vs control | RR 2.53 [0.27, 23.85] | 6 studies · 1593 participants | Moderate Downgraded: risk of bias |
Somnolence Oxcarbazepine vs control | RR 2.03 [1.17, 3.54] | 6 studies · 1593 participants | Low Downgraded: risk of bias |
Seizure freedom Oxcarbazepine vs control | RR 2.86 [1.19, 6.87] | 5 studies · 1494 participants | Low Downgraded: risk of bias |
Treatment withdrawal Oxcarbazepine vs control | RR 1.75 [1.44, 2.13] | 6 studies · 1593 participants | Moderate Downgraded: risk of bias |